---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-074280"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:09:18.819333+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Medicare finalizes coverage for Renalytix's kidneyIntelX.dkd at $950/test effective Aug 1, 2024

## Summary
- Medicare issued final Local Coverage Determination (LCD) for kidneyIntelX.dkd; effective dates of service on/after August 1, 2024.
- Established Medicare price is $950 per test; distinct CPT codes published in CMS 2024 Clinical Lab Fee Schedule.
- Coverage applies to patients with Type 2 diabetes and Stage 1-3b Chronic Kidney Disease per FDA label.
- LCD issued by National Government Services (NGS), a Medicare Administrative Contractor for the company's NYC lab.
- CEO expects coverage to prompt additional major insurance decisions and accelerate test adoption.

## SEC filing metadata
- accession: 0000950170-24-074280
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024074280/0000950170-24-074280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024074280/rnlx-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-074280
- JSON: https://secwatch.observer/filing/0000950170-24-074280.json
- Plain text: https://secwatch.observer/filing/0000950170-24-074280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.